Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte (TIL) therapies for the treatment of cancer. Instil has assembled an accomplished management team with a successful track record in the development, manufacture, and commercialization of cell therapies. Instil is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma and other solid tumors as well as ITIL-306, a next-generation, genetically engineered TIL therapy for multiple solid tumors.